Publications by authors named "K Koster"
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression commonly occurs. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
View Article and Find Full Text PDFArticle Synopsis
- A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
- Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
- The treatment was generally well-t
The Food and Drug Administration and the Federal Trade Commission influence the contact lens (CL) market, with the Food and Drug Administration regulating CLs as medical devices and the Federal Trade Commission dictating how they are prescribed and sold. Legislative oversight came to the forefront in 2004, when the Contact Lens Rule was introduced, drastically changing how CLs are prescribed and distributed. This article examines the evolution of CL regulations over the past two decades and discusses how regulation, such as allowing passive verification, has shaped the current and evolving CL market.
View Article and Find Full Text PDFBackground: Advanced education of midwives acting during the first 1000 days in life is key in optimum care provision for intergenerational health and wellbeing.
Aim: This paper provides a comprehensive analysis of the current context of midwifery care and (inter)national trends in midwifery education. Gaps for optimizing midwifery education in Belgium are defined.
Background: Multitarget stool DNA (mt-sDNA) is an increasingly utilized noninvasive option for colorectal cancer screening; however, its impact is limited by imperfect test adherence. Tailored patient navigation (TPN) improves adherence for other cancer screening tests, but its role in mt-sDNA is not known.
Aim: Determine whether TPN improves mt-sDNA completion and reduces sample could not be processed (SCNBP) result rates.